Index RUT
P/E -
EPS (ttm) -7.69
Insider Own 18.38%
Shs Outstand 60.05M
Perf Week 8.22%
Market Cap 950.12M
Forward P/E -
EPS next Y -2.82
Insider Trans 0.96%
Shs Float 49.02M
Perf Month 13.42%
Income -262.59M
PEG -
EPS next Q -0.54
Inst Own 79.08%
Short Float 27.11%
Perf Quarter 6.05%
Sales 10.78M
P/S 88.14
EPS this Y 26.27%
Inst Trans -0.12%
Short Ratio 16.51
Perf Half Y -29.62%
Book/sh 4.23
P/B 3.74
EPS next Y 28.83%
ROA -155.54%
Short Interest 13.29M
Perf Year 111.53%
Cash/sh 4.64
P/C 3.41
EPS next 5Y -
ROE -199.56%
52W Range 6.65 - 30.96
Perf YTD 47.87%
Dividend Est. -
P/FCF -
EPS past 5Y -48.48%
ROI -102.45%
52W High -48.89%
Beta 1.78
Dividend TTM -
Quick Ratio 7.12
Sales past 5Y 0.00%
Gross Margin 87.40%
52W Low 137.93%
ATR (14) 0.99
Dividend Ex-Date -
Current Ratio 7.12
EPS Y/Y TTM -249.14%
Oper. Margin -2518.49%
RSI (14) 58.54
Volatility 5.63% 6.48%
Employees 55
Debt/Eq 0.01
Sales Y/Y TTM 62.73%
Profit Margin -2435.02%
Recom 1.00
Target Price 30.60
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -32.29%
Payout -
Rel Volume 0.58
Prev Close 15.97
Sales Surprise 26.64%
EPS Surprise -58.14%
Sales Q/Q -44.55%
Earnings Aug 12 AMC
Avg Volume 804.72K
Price 15.82
SMA20 6.98%
SMA50 11.40%
SMA200 0.15%
Trades
Volume 385,542
Change -0.93%
Date
Action
Analyst
Rating Change
Price Target Change
May-31-24 Initiated
Piper Sandler
Overweight
$27
Apr-30-24 Initiated
JP Morgan
Overweight
$24
Apr-15-24 Initiated
Guggenheim
Buy
$35
Jan-29-24 Initiated
Leerink Partners
Outperform
$30
Dec-19-23 Initiated
Wedbush
Outperform
$12
Oct-29-21 Initiated
Cantor Fitzgerald
Overweight
$35
Sep-13-24 07:00AM
Aug-29-24 08:00AM
Aug-20-24 03:26PM
(Investor's Business Daily) +6.36%
Aug-12-24 05:15PM
04:01PM
08:00AM
Loading…
Jul-25-24 08:00AM
07:30AM
Jul-09-24 07:00AM
Jun-27-24 08:00AM
May-22-24 02:05PM
May-21-24 07:01PM
May-20-24 11:14AM
08:00AM
May-17-24 08:51AM
08:00AM
01:54PM
Loading…
May-14-24 01:54PM
09:10AM
08:00AM
May-08-24 08:00AM
May-02-24 08:00AM
Apr-30-24 07:29AM
Apr-26-24 10:00AM
Apr-25-24 08:26AM
Apr-05-24 08:00AM
Mar-28-24 11:53PM
04:02PM
Mar-26-24 08:00AM
08:00AM
Mar-18-24 05:44AM
Mar-07-24 08:00AM
07:00AM
Loading…
Mar-04-24 07:00AM
Mar-01-24 08:00AM
Feb-20-24 08:15AM
08:00AM
Feb-16-24 04:05PM
Feb-13-24 10:38PM
04:05PM
Feb-07-24 08:34AM
Feb-06-24 09:20AM
(FierceBiotech.com) +36.91%
08:00AM
Feb-05-24 08:00AM
Jan-08-24 07:00AM
Jan-04-24 08:00AM
Jan-03-24 08:00AM
Jan-02-24 08:00AM
Dec-26-23 08:30AM
08:30AM
Nov-10-23 08:00AM
Nov-09-23 08:00AM
Nov-08-23 08:00AM
Oct-23-23 02:50AM
Oct-19-23 08:00AM
Oct-04-23 11:00PM
Oct-03-23 08:00AM
Aug-17-23 08:19PM
(American City Business Journals)
Aug-09-23 08:00AM
Jun-30-23 09:51AM
Jun-29-23 09:00AM
Jun-02-23 07:55AM
May-23-23 04:05PM
May-09-23 08:50AM
May-05-23 08:00AM
Apr-20-23 08:50AM
Mar-16-23 08:00AM
Mar-13-23 07:32AM
Mar-09-23 08:45AM
Feb-08-23 08:00AM
Jan-31-23 06:52AM
Jan-06-23 04:05PM
(Investor's Business Daily)
-15.47%
02:46PM
(American City Business Journals)
10:35AM
08:00AM
Nov-14-22 08:00AM
Nov-09-22 12:00PM
Oct-04-22 06:08AM
Aug-24-22 06:59AM
Aug-23-22 09:00AM
Aug-05-22 08:00AM
Jul-06-22 09:28AM
08:00AM
Jun-09-22 08:00AM
Jun-02-22 08:00AM
May-26-22 08:07AM
May-23-22 08:00AM
May-19-22 03:27PM
11:31AM
(American City Business Journals)
08:00AM
May-12-22 08:00AM
Mar-28-22 08:00AM
Mar-17-22 06:40AM
Mar-14-22 12:30PM
Mar-11-22 10:48AM
08:00AM
Feb-08-22 03:00PM
10:22AM
(American City Business Journals)
08:00AM
Jan-11-22 09:56AM
(American City Business Journals)
06:46AM
Jan-10-22 04:15PM
Dec-17-21 07:11AM
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIENAIME JEAN JACQUES Director Aug 16 '24 Buy 13.94 7,000 97,608 16,615 Aug 19 09:07 PM Higgins Jack Chief Scientific Officer Aug 15 '24 Option Exercise 1.35 19,524 26,357 19,524 Aug 19 09:05 PM Higgins Jack Chief Scientific Officer Aug 15 '24 Sale 13.93 3,524 49,072 16,000 Aug 19 09:05 PM Higgins Jack Officer Aug 15 '24 Proposed Sale 13.93 3,524 49,073 Aug 15 03:21 PM BIENAIME JEAN JACQUES Director May 21 '24 Buy 13.57 2,000 27,140 9,615 May 22 04:49 PM SIEGALL CLAY B President and CEO May 20 '24 Buy 13.91 79,566 1,106,524 399,202 May 21 04:13 PM SIEGALL CLAY B President and CEO May 21 '24 Buy 13.78 20,434 281,548 419,636 May 21 04:13 PM SIEGALL CLAY B President and CEO Oct 02 '23 Buy 5.91 169,204 999,996 319,636 Oct 04 05:35 PM Turner Bruce Chief Strategy Officer Oct 02 '23 Buy 5.91 42,300 249,993 42,300 Oct 04 05:32 PM
Index -
P/E 53.19
EPS (ttm) 1.32
Insider Own 1.26%
Shs Outstand 188.60M
Perf Week -16.45%
Market Cap 13.41B
Forward P/E 22.60
EPS next Y 3.12
Insider Trans -6.26%
Shs Float 187.99M
Perf Month -20.99%
Income 256.59M
PEG 1.24
EPS next Q 0.53
Inst Own 98.52%
Short Float 3.11%
Perf Quarter -15.63%
Sales 2.59B
P/S 5.18
EPS this Y 131.03%
Inst Trans 2.05%
Short Ratio 2.83
Perf Half Y -15.99%
Book/sh 27.77
P/B 2.54
EPS next Y 55.11%
ROA 3.76%
Short Interest 5.85M
Perf Year -19.64%
Cash/sh 6.43
P/C 10.96
EPS next 5Y 43.00%
ROE 5.10%
52W Range 73.68 - 99.56
Perf YTD -26.93%
Dividend Est. -
P/FCF 58.12
EPS past 5Y -
ROI 4.36%
52W High -29.23%
Beta 0.33
Dividend TTM -
Quick Ratio 1.95
Sales past 5Y 10.23%
Gross Margin 77.79%
52W Low -4.37%
ATR (14) 3.06
Dividend Ex-Date -
Current Ratio 3.05
EPS Y/Y TTM 154.18%
Oper. Margin 10.02%
RSI (14) 19.08
Volatility 1.67% 2.46%
Employees 3401
Debt/Eq 0.21
Sales Y/Y TTM 18.10%
Profit Margin 9.91%
Recom 1.61
Target Price 112.52
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 87.65%
Payout 0.00%
Rel Volume 4.61
Prev Close 84.90
Sales Surprise 7.24%
EPS Surprise 53.72%
Sales Q/Q 19.18%
Earnings Aug 05 AMC
Avg Volume 2.06M
Price 70.46
SMA20 -20.65%
SMA50 -18.68%
SMA200 -19.30%
Trades
Volume 7,893,970
Change -17.01%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-20-24 Upgrade
Bernstein
Mkt Perform → Outperform
$94 → $110
May-17-24 Downgrade
Robert W. Baird
Outperform → Neutral
$104 → $72
May-14-24 Initiated
Evercore ISI
Outperform
$113
Nov-15-23 Initiated
Wells Fargo
Overweight
$100
Oct-23-23 Upgrade
Bernstein
Underperform → Mkt Perform
$82
Sep-28-23 Initiated
Raymond James
Mkt Perform
Sep-18-23 Initiated
UBS
Buy
$120
Jul-27-23 Initiated
Scotiabank
Sector Perform
$95
Jul-05-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$102
Jun-14-23 Resumed
Credit Suisse
Outperform
$120
Mar-21-23 Initiated
Bernstein
Underperform
$81
Feb-22-23 Downgrade
Oppenheimer
Outperform → Perform
Feb-21-23 Initiated
Citigroup
Neutral
$116
Jan-30-23 Initiated
BMO Capital Markets
Market Perform
$107
Jan-18-23 Initiated
Canaccord Genuity
Hold
$119
Oct-31-22 Upgrade
Oppenheimer
Perform → Outperform
$92 → $110
Jul-13-22 Initiated
Cantor Fitzgerald
Overweight
$110
Jun-13-22 Resumed
Wedbush
Neutral
$146 → $70
Apr-25-22 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$96 → $113
Nov-22-21 Upgrade
William Blair
Mkt Perform → Outperform
Show Previous Ratings
Today 10:24AM
(Investor's Business Daily) -17.01%
Sep-13-24 09:45AM
Sep-08-24 02:03AM
Sep-04-24 01:30PM
01:00PM
11:30AM
Loading…
11:30AM
07:30AM
Aug-29-24 11:53AM
(Pharmaceutical Technology)
09:50AM
08:15AM
08:00AM
04:12AM
(Pharmaceutical Technology)
Aug-28-24 12:45PM
09:45AM
Aug-23-24 07:56AM
08:30AM
Loading…
Aug-21-24 08:30AM
07:00AM
Aug-19-24 09:00AM
Aug-13-24 10:34AM
09:50AM
Aug-12-24 12:45PM
Aug-09-24 09:15AM
Aug-06-24 02:42PM
(The Wall Street Journal) +7.95%
01:35PM
(Thomson Reuters StreetEvents)
11:51AM
10:35AM
07:45AM
Aug-05-24 06:00PM
05:15PM
04:15PM
(Associated Press Finance)
04:03PM
Loading…
04:03PM
04:01PM
Jul-31-24 09:15AM
Jul-25-24 06:33AM
(Pharmaceutical Technology)
Jul-24-24 04:05PM
12:10PM
Jul-23-24 08:00AM
Jul-22-24 10:01AM
Jul-15-24 08:41AM
Jul-01-24 09:20AM
Jun-20-24 03:18AM
Jun-17-24 08:30AM
Jun-11-24 10:57AM
Jun-07-24 06:09PM
09:00AM
Jun-05-24 06:14AM
Jun-04-24 08:00AM
May-25-24 11:10PM
May-24-24 11:31AM
May-18-24 05:06AM
May-15-24 07:00AM
May-13-24 04:14PM
May-09-24 06:15AM
May-08-24 08:00AM
May-06-24 07:00PM
04:47PM
May-04-24 04:00PM
May-03-24 02:31PM
Apr-29-24 02:26PM
Apr-27-24 05:06AM
01:07AM
Apr-26-24 08:49AM
06:53AM
Apr-25-24 01:30PM
11:48AM
11:44AM
10:47AM
10:31AM
07:39AM
06:46AM
(Thomson Reuters StreetEvents)
03:19AM
Apr-24-24 06:30PM
05:33PM
05:15PM
04:23PM
04:14PM
(Associated Press Finance)
04:03PM
Apr-23-24 11:36AM
Apr-22-24 04:26PM
09:16AM
Apr-17-24 10:01AM
Apr-12-24 07:00PM
Apr-10-24 08:00AM
Apr-01-24 07:01PM
Mar-17-24 08:50AM
Mar-16-24 05:06AM
Mar-12-24 08:30AM
Mar-11-24 10:00AM
Mar-08-24 01:31AM
Mar-07-24 08:30AM
Mar-01-24 09:00AM
Feb-27-24 12:03AM
Feb-26-24 02:36PM
02:12PM
Feb-23-24 04:29PM
12:33PM
11:34AM
07:21AM
(Thomson Reuters StreetEvents)
05:43AM
04:25AM
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burkhart Erin GVP, Chief Accounting Officer Aug 13 '24 Sale 90.00 714 64,260 14,449 Aug 15 03:57 PM Burkhart Erin Officer Aug 13 '24 Proposed Sale 90.00 714 64,260 Aug 13 11:48 AM HERON ELAINE J Director Jun 03 '24 Option Exercise 63.10 5,047 318,466 101,888 Jun 04 07:29 PM MEIER RICHARD A Director Jun 03 '24 Option Exercise 63.10 6,600 416,460 126,227 Jun 04 07:28 PM Mueller Brian EVP, Chief Financial Officer May 30 '24 Option Exercise 63.10 5,000 315,500 77,159 May 31 06:28 PM Mueller Brian EVP, Chief Financial Officer May 30 '24 Sale 75.19 5,000 375,950 72,159 May 31 06:28 PM Davis George Eric EVP, Chief Legal Officer May 28 '24 Option Exercise 63.10 40,850 2,577,635 97,007 May 30 06:18 PM Davis George Eric EVP, Chief Legal Officer May 28 '24 Sale 74.51 40,850 3,043,802 56,157 May 30 06:18 PM BIENAIME JEAN JACQUES Director May 09 '24 Option Exercise 63.10 20,000 1,262,000 494,994 May 13 03:57 PM BIENAIME JEAN JACQUES Director May 10 '24 Option Exercise 63.10 20,000 1,262,000 494,994 May 13 03:57 PM BIENAIME JEAN JACQUES Director May 09 '24 Sale 81.62 20,000 1,632,400 474,994 May 13 03:57 PM BIENAIME JEAN JACQUES Director May 10 '24 Sale 81.14 20,000 1,622,800 474,994 May 13 03:57 PM Davis George Eric EVP, Chief Legal Officer May 02 '24 Option Exercise 63.10 1,850 116,735 58,007 May 06 04:45 PM Davis George Eric EVP, Chief Legal Officer May 02 '24 Sale 85.01 1,850 157,268 56,157 May 06 04:45 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer May 02 '24 Sale 82.91 5,000 414,550 66,767 May 06 04:40 PM BIENAIME JEAN JACQUES Director Apr 11 '24 Option Exercise 63.10 20,000 1,262,000 494,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 12 '24 Option Exercise 63.10 20,000 1,262,000 494,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 12 '24 Sale 91.26 20,000 1,825,200 474,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 11 '24 Sale 90.99 20,000 1,819,800 474,994 Apr 15 04:21 PM Burkhart Erin GVP, Chief Accounting Officer Apr 10 '24 Sale 90.00 2,286 205,740 16,156 Apr 12 03:07 PM Davis George Eric EVP, Chief Legal Officer Mar 28 '24 Sale 88.34 24,602 2,173,341 55,856 Apr 01 04:54 PM Slamon Dennis Director Mar 18 '24 Option Exercise 79.70 10,000 797,000 40,809 Mar 20 05:13 PM FUCHS HENRY J President, Worldwide R&D Mar 05 '24 Sale 85.18 35,341 3,010,396 212,117 Mar 07 06:54 PM BIENAIME JEAN JACQUES Director Mar 06 '24 Sale 86.71 1,000 86,713 560,203 Mar 07 05:35 PM BIENAIME JEAN JACQUES Director Mar 05 '24 Sale 85.51 1,000 85,510 561,203 Mar 07 05:35 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 05 '24 Sale 87.07 4,000 348,280 94,047 Mar 07 05:32 PM BIENAIME JEAN JACQUES Director Feb 27 '24 Sale 90.35 1,000 90,350 562,203 Feb 29 05:05 PM BIENAIME JEAN JACQUES Director Feb 08 '24 Option Exercise 63.10 15,000 946,500 434,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 09 '24 Option Exercise 63.10 15,000 946,500 434,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 08 '24 Sale 89.77 15,000 1,346,550 419,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 09 '24 Sale 88.28 15,000 1,324,200 419,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Jan 09 '24 Option Exercise 63.10 10,000 631,000 435,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 10 '24 Option Exercise 63.10 10,000 631,000 435,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 09 '24 Sale 98.19 10,000 981,900 425,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 10 '24 Sale 96.38 10,000 963,800 425,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Dec 21 '23 Option Exercise 63.10 10,000 631,000 435,112 Dec 22 05:14 PM BIENAIME JEAN JACQUES Director Dec 21 '23 Sale 93.99 10,000 939,900 425,112 Dec 22 05:14 PM Davis George Eric EVP, Chief Legal Officer Dec 13 '23 Sale 95.30 13,764 1,311,709 55,710 Dec 14 06:18 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite